Specifically, our experiments were performed not only in HER2-positive BC and GC patients, for whom anti-HER2 treatments are currently recommended1,2, but also in CRC, where novel dual anti-HER2 combinations, such as trastuzumab + lapatinib or trastuzumab + pertuzumab, are considered highly promising in heavily pretreated patients3,12. The gene discussed is ERBB2; the disease is colorectal carcinoma.